Delving into the Latest Updates on Melacure Therapeutics AB with Synapse

Overview

A review.This article will give a brief overview of the pharmacol. of the melanocortin receptors (MCRs) as a background.The review will not handle the patents or patent applications dealing with cloning of the different subtypes of the receptor, since this has been recently reviewed [1].This review will focus on different ligands acting either as agonists or antagonists to the different subtypes of the receptor, i.e., MC₁R, MC₃R, MC₄R and MC₅R.Just recently a number of patent applications have reached the public domain, which describe small peptides or low mol. weight organic compounds binding and acting on the MCRs.

100 Deals associated with Melacure Therapeutics AB

Login to view more data

100 Translational Medicine associated with Melacure Therapeutics AB

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

ME-10393 (Melacure) ( melanocortin receptor )	Dermatitis More	Discontinued
HS-131 ( MC4R )	Opium Dependence More	Discontinued
PR-5 ( Xanthine oxidase )	Reperfusion Injury More	Discontinued